"Abbott touts long-term efficacy for dissolvable Esprit BTK stent" was originally created and published by Medical Device ...

Media tour conducted in conjunction with D S Simon Media discussing Peripheral Artery Disease (PAD), one of the most prevalent diseases that no one has heard of, affecting one in 20 Americans over the ...

Abbott has delivered new, longer-term data from a clinical study of its dissolving stent for severe peripheral artery disease ...

Interventional cardiologist Dr. Ross Melvin joins us to give a demonstration of the new technology available to treat peripheral arterial disease.

Following a greenlight from the US FDA, Philips has enrolled the first patient in a trial of its newest intravascular ...

The muscle cells lining an artery resemble a stained glass window in this image, the winner of the British Heart Foundation’s ...

Abbott (NYSE:ABT) today announced data demonstrating the long-term effectiveness of its Esprit BTK drug-eluting stent.

Royal Philips announced enrollment of the first patient in THOR, a United States investigational device exemption (IDE) clinica ...

A risk model accurately identifies patients with severe asymptomatic carotid artery stenosis and predicts their risk for stroke and CVD.

Philips announced the first U.S. treatment using its new laser device that combines two peripheral artery disease (PAD) procedures into one.

With a unique world-first ability to perform laser atherectomy and laser-based intravascular lithotripsy using a single ...